Pravastatin
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Pravastatin |
| DrugBank ID | DB00175 |
| Brand Names (EU) | Pravafenix, Pravastatin |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.95% |
Approved Indication (EMA)
Pravafenix is indicated as an adjunct to diet and other non-pharmacological treatment (e.g. exercise, weight reduction) for the treatment of mixed hyperlipidaemia in adult patients at high cardiovascular risk to reduce triglycerides and increase HDL C when LDL C levels are adequately controlled while on a treatment with pravastatin 40 mg monotherapy or on another moderate-intensity statin regimen.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | homozygous familial hypercholesterolemia | 99.95% | DL |
| 2 | obsolete familial combined hyperlipidemia | 99.82% | DL |
| 3 | HIV infectious disease | 99.74% | DL |
| 4 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 99.62% | DL |
| 5 | feline acquired immunodeficiency syndrome | 99.55% | DL |
| 6 | simian immunodeficiency virus infection | 99.55% | DL |
| 7 | hyperlipoproteinemia | 99.43% | DL |
| 8 | familial hypercholesterolemia | 99.34% | DL |
| 9 | hypoalphalipoproteinemia | 99.21% | DL |
| 10 | hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency | 99.07% | DL |
| 11 | cholesterol-ester transfer protein deficiency | 99.04% | DL |
| 12 | hyperlipidemia, familial combined, LPL related | 98.87% | DL |
| 13 | obsolete susceptibility to ischemic stroke | 98.76% | DL |
| 14 | hypercholesterolemia, autosomal dominant | 98.69% | DL |
| 15 | familial hyperlipidemia | 98.54% | DL |
| 16 | brain stem infarction | 98.42% | DL |
| 17 | hyperlipidemia due to hepatic triglyceride lipase deficiency | 98.17% | DL |
| 18 | hypolipoproteinemia (disease) | 98.12% | DL |
| 19 | hyperlipidemia | 98.05% | DL |
| 20 | cerebral infarction | 97.92% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.